🟠 Conclusions: Vertex faces increased scrutiny as investors evaluate suzetrigine’s viability, with litigation and stock recovery hinging on Phase 3 trial outcomes. #CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA